Autoimmune Diseases  >>  Mayzent (siponimod)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mayzent (siponimod) / Novartis
NCT01185821 / 2009-014392-51: Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

Completed
2
185
US, Canada, Europe, RoW
BAF312, siponimod
Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
10/16
10/16

Download Options